UPCC 04423: Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and an Anti-CD38 Antibody
Enrolling By Invitation
99 years and younger
All
1 Location
Brief description of study
Compassionate use access to belantamab mafodotin (GSK2857916) for eligible participants with refractory/relapsing multiple myeloma.
We would like to rely on WCG as the IRB of record for this study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
Updated on
12 Apr 2023.
Study ID: 853214
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
